On June 4, 2019, the Company acquired Vilex, a manufacturer of foot and ankle surgical implants. Since the Vilex products include adult offerings that are not core to the Company's pediatric business, the Company received Board approval to take the steps necessary to divest the non-core Vilex assets. As a result, certain assets and liabilities of Vilex are classified as held for sale on the condensed consolidated balance sheet as of June 30, 2019.

The following summarized financial information has been segregated from continuing operations and reported as discontinued operations for the three and six months ended June 30, 2019:


	Three and Six Months Ended
	June 30, 2019
Revenue	$	414
Operating expenses	507
Depreciation and amortization	66
Operating loss	(159)

Loss from discontinued operations	$	(159)

The assets and liabilities held for sale on the condensed consolidated balance sheet as of June 30, 2019 are as follows:


	June 30, 2019
Assets:
Cash	$	360
Accounts receivable	850
Inventories	2,163
Prepaid expenses and other current assets	12
Property and equipment	6,015
Amortizable intangible assets	5,452
Goodwill	18,022
Operating lease right-of-use asset	240
Other intangible assets	2,250
Current assets held for sale, net	35,364
Liabilities:
Accounts payable	71
Accrued compensation and benefits	159
Operating lease liabilities	239
Other current liabilities	25
Liabilities held for sale	$	494